Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
108.60    6.60 (6.47%)
Bid:
108.40
Ask:
109.60
Spread: 1.20 (1.107%)
Market Cap: £178.04m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Receivables purchasing arrangement

18 Dec 2025 07:00

RNS Number : 0195M
Synthomer PLC
18 December 2025
 

Synthomer plcReceivables purchasing arrangement

 

Synthomer plc ('Synthomer' or the 'Company') today announces that it has entered into a trade receivables purchasing arrangement with Rainbow State Limited, a subsidiary of its largest shareholder Kuala Lumpur Kepong Berhad Group ('KLK'). The Company has put this temporary arrangement in place with the support of KLK to provide additional short-term financial flexibility and ensure a prudent level of banking covenant headroom at year end.

 

Under the arrangement, the Company and KLK have agreed that KLK will purchase c.£50m of Company trade receivables due on or before 28 February 2026, which are not eligible for inclusion in the Company's existing committed €200m non-recourse receivables financing facility. It is anticipated that receivables purchased under the arrangement and in the existing committed receivables financing facility together will not exceed €200m (c.£175m). The purchasing arrangement terms have been agreed on an arms-length basis and are consistent with terms available from third party market participants for an arrangement of this nature.

 

Related party transaction

By virtue of KLK and its connected parties' c.27 per cent shareholding in Synthomer, KLK is considered a related party of Synthomer under the UK Listing Rules. The board of Synthomer (excluding Dato' Lee Hau Hian and Uwe Halder by reason of their relationship with KLK) considers that the purchasing arrangement is fair and reasonable as far as Synthomer shareholders are concerned, and have been so advised by Rothschild & Co acting in its capacity as sponsor in relation to this related party transaction.

 

Post-close trading update

Synthomer plans to publish its post-close trading update for the year ending 31 December 2025 in late January.

 

 

Further information:

Investors: Faisal Tabbah, Vice President Investor Relations

Tel: +44 (0) 1279 775 306

Media: Nick Hasell, FTI Consulting

Tel: +44 (0) 203 727 1340

 

Notes

Synthomer plc is a leading supplier of high-performance, highly specialised polymers and ingredients that play vital roles in key sectors such as coatings, construction, adhesives, and health and protection - growing markets for customers who serve billions of end users worldwide. Headquartered in London, UK and listed there since 1971, we employ c.3,800 employees across our five innovation centres of excellence and 29 manufacturing sites across Europe, North America, Middle East and Asia. With more than 6,000 blue-chip customers and £2.0bn in continuing revenue in 2024, our business is built around three divisions, serving customers in attractive end markets where demand is driven by global megatrends including urbanisation, demographic change, climate change and sustainability, and shifting economic power.

 

In Coatings & Construction Solutions, our specialist polymers enhance the sustainability and performance of a wide range of coatings and construction products. We serve customers in applications including architectural and masonry coatings, mortar modification, waterproofing and flooring, fibre bonding, and energy solutions. In Adhesive Solutions our products help our customers bond, modify and compatibilise surfaces and components for applications including tapes and labels, packaging, hygiene, tyres and plastic modification, improving permeability, strength, elasticity, damping, dispersion and grip. In Health & Protection and Performance Materials we are a world-leading supplier of water-based polymers for medical gloves, and a major European manufacturer of high-performance binders, foams and other products serving customers in a range of end markets.

 

Our purpose is creating innovative and sustainable solutions for the benefit of customers and society. Around 20% of our sales volumes are from new and patent protected products. At our innovation centres of excellence in the UK, China, Germany, Malaysia and Ohio, USA we collaborate closely with our customers to develop new products and enhance existing ones tailored to their needs, with an increasing range of sustainability benefits. Our 2030 decarbonisation targets have been approved by the Science Based Targets initiative as being in line with what the latest climate science says is necessary to meet the goals of the Paris Agreement, and since 2021 we have held the London Stock Exchange Green Economy Mark, which recognises green technology businesses making a significant contribution to a more sustainable, low-carbon economy. Find us at www.synthomer.com or search for Synthomer on LinkedIn.

 

N. M. Rothschild and Sons Limited ('Rothschild & Co'), which is authorised and regulated by the FCA in the United Kingdom, is acting exclusively for the Company and no one else in connection with the receivables purchasing arrangement and will not be responsible to any other person for providing the protections afforded to its clients or for providing advice in connection with the receivables purchasing arrangement, the contents of this announcement or any other matter referred to herein.

 

Apart from the responsibilities and liabilities, if any, which may be imposed on Rothschild & Co by the FSMA or the regulatory regime established thereunder, or under the regulatory regime of any jurisdiction where the exclusion of liability under the relevant regulatory regime would be illegal, void or unenforceable, neither Rothschild & Co nor any of its affiliates (nor their respective directors, officers, employees or agents) owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Rothschild & Co in connection with this announcement, any statement contained herein, the receivables purchasing arrangement or otherwise. Rothschild & Co. accepts no responsibility whatsoever for, or makes any representation or warranty, express or implied, as to the contents of this announcement, including its accuracy, completeness or verification or for any other statement made or purported to be made by it, or on its behalf, and nothing contained in this document is, or shall be, relied on as a promise or representation in this respect, whether as to the past or the future, in connection with the Company or the receivables purchasing arrangement. Rothschild & Co. and its respective subsidiaries, branches and affiliates accordingly disclaim, to the fullest extent permitted by law, all and any duty, liability and responsibility whether arising in tort, contract or otherwise (save as referred to above) in respect of this announcement or any such statement or otherwise.

 

Legal Entity Identifier (LEI): 213800EHT3TI1KPQQJ56.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRFZMMZRNVGKZM
Date   Source Headline
6th Oct 20238:53 amRNSHolding(s) in Company
5th Oct 20232:40 pmRNSDirector/PDMR Shareholding
5th Oct 202312:27 pmRNSHolding(s) in Company
2nd Oct 20232:22 pmRNSHolding(s) in Company
28th Sep 20237:00 amRNSAdmission of Nil Paid Rights
27th Sep 20237:00 amRNSDespatch of PALs
26th Sep 20237:00 amRNSCapital Reorganisation
25th Sep 20231:58 pmRNSResults of General Meeting
22nd Sep 20233:21 pmRNSAdditional Listing
7th Sep 20233:44 pmRNSPublication of a Prospectus
7th Sep 20237:00 amRNSRights Issue
7th Sep 20237:00 amRNSHalf-year results
18th Jul 20237:00 amRNSPost-close trading update
12th Jul 20233:17 pmRNSAppointment of Non-Executive Director
28th Jun 202312:37 pmRNSDirector/PDMR Shareholding
28th Jun 202312:36 pmRNSDirector/PDMR Shareholding
22nd Jun 202310:20 amRNSDirector/PDMR Shareholding
16th May 20234:00 pmRNSResult of AGM
16th May 20237:00 amRNSAGM trading update
12th May 20231:08 pmRNSDirector/PDMR Shareholding
12th May 20231:06 pmRNSDirector/PDMR Shareholding
13th Apr 202310:02 amRNSHolding(s) in Company
12th Apr 20235:52 pmRNS2022 Annual Financial Report & Notice of 2023 AGM
11th Apr 20237:00 amRNSDirector/PDMR Shareholding
11th Apr 20237:00 amRNSDirector/PDMR Shareholding
29th Mar 20237:00 amRNSDirector/PDMR Shareholding
29th Mar 20237:00 amRNSDirector/PDMR Shareholding
29th Mar 20237:00 amRNSDirector/PDMR Shareholding
28th Mar 20237:00 amRNSFinal Results
21st Mar 20237:00 amRNSRefinancing
28th Feb 20233:33 pmRNSDisposal
31st Jan 20237:00 amRNSPost-close update for the year ended 31 Dec 2022
11th Jan 202311:30 amRNSResult of General Meeting
16th Dec 202212:12 pmRNSPublication of Circular &Notice of General Meeting
13th Dec 20227:00 amRNSProposed Sale of Laminates, Films & Coated Fabrics
8th Dec 20227:00 amRNSDirector/PDMR Shareholding
30th Nov 20227:00 amRNSBoard changes
29th Nov 202211:16 amRNSOutcome of European Commission investigation
1st Nov 20222:53 pmRNSHolding(s) in Company
27th Oct 202210:27 amRNSHolding(s) in Company
25th Oct 20227:00 amRNSDirector/PDMR Shareholding
25th Oct 20227:00 amRNSDirector/PDMR Shareholding
20th Oct 20227:00 amRNSCovenant relaxation to the end of 2023 agreed
13th Oct 20227:00 amRNSHolding(s) in Company
12th Oct 20227:00 amRNSInvestor Seminar
6th Oct 20227:00 amRNSDirector/PDMR Shareholding
6th Oct 20227:00 amRNSDirector/PDMR Shareholding
6th Oct 20227:00 amRNSDirector/PDMR Shareholding
4th Oct 202210:40 amRNSDirector/PDMR Shareholding
4th Oct 202210:37 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.